The "critical thrombosis period" in major orthopedic surgery: When to start and when to stop prophylaxis

Clinical and Applied Thrombosis/Hemostasis

Volumn 16, Issue 4, 2010, Pages 394-405

  Warwick, David ^a   Rosencher, Nadia ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b Université René Descartes ^*  (France)

Author keywords

deep vein thrombosis; hip arthroplasty; knee arthroplasty; prophylaxis; pulmonary embolism; venous thromboembolism

Indexed keywords

ANTIVITAMIN K; DABIGATRAN; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; RIVAROXABAN; TINZAPARIN;

BLEEDING; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; MORBIDITY; MORTALITY; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOGENESIS; THROMBOSIS; TOTAL HIP PROSTHESIS; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; HEPARIN; HUMANS; ORTHOPEDIC PROCEDURES; POSTOPERATIVE COMPLICATIONS; VENOUS THROMBOEMBOLISM;

EID: 77954942097     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029609355151     Document Type: Review

References (66)

1. Geerts WH, Bergqvist D., Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8 th Edition). Chest. 2008 ; 133 (suppl). 381S - 453S.
2. Cardiovascular Disease Educational and Research Trust; Cyprus Cardiovascular Disease Educational and Research Trust; European Venous Forum; International Surgical Thrombosis Forum; International Union of Angiology; Union Internationale de Phlébologie. Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol. 2006 ; 25 (2). 101-161.
3. Bjørnarå BT, Gudmundsen TE, Dahl OE Frequency and timing of clinical venous thromboembolism after major joint surgery. J Bone Joint Surg Br. 2006 ; 88 (3). 386-391.
4. Hull RD, Pineo GF, Stein PD, et al. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med. 2001 ; 161 (16). 1952-1960.
5. Hull RD, Brant RF, Pineo GF, Stein PD, Raskob GE, Valentine KA Preoperative vs postoperative initiation of low-molecular-weight heparin prophylaxis against venous thromboembolism in patients undergoing elective hip replacement. Arch Intern Med. 1999 ; 159 (2). 137-141.
6. Hull RD, Pineo GF, Francis C., et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Arch Intern Med. 2000 ; 160 (14). 2208-2215.
7. Leclerc JR, Gent M., Hirsch J., Geerts WH, Ginsberg JS The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group. Arch Intern Med. 1998 ; 158 (8). 873-878. (Pubitemid 28183642)
8. Planes A., Vochelle N., Darmon JY, Fagola M., Bellaud M., Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet. 1996 ; 348 (9022). 224-228.
9. Bergqvist D., Benoni G., Björgell O., et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med. 1996 ; 335 (10). 696-700.
10. White RH, Romano PS, Zhou H., Rodrigo J., Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med. 1998 ; 158 (14). 1525-1531.
11. Dahl OE, Gudmundsen TE, Haukeland L. Late occurring clinical deep vein thrombosis in joint-operated patients. Acta Orthop Scand. 2000 ; 71 (1). 47-50.
12. White RH, Zhou H., Romano PS Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost. 2003 ; 90 (3). 446-455.
13. Oster G., Ollendorf DA, Vera-Llonch M., Hagiwara M., Berger A., Edelsberg J. Economic consequences of venous thromboembolism following major orthopaedic surgery. Ann Pharmacother. 2004 ; 38 (3). 377-382.
14. Warwick D., Friedman RJ, Agnelli G., et al. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br. 2007 ; 89 (10). 799-807.
15. Dahl OE, Andreassen G., Aspelin T., et al. Prolonged thromboprophylaxis following hip replacement surgery-results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin). Thromb Haemost. 1997 ; 77 (1). 26-31.
16. Lassen MR, Borris LC, Anderson BS, et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty-the Danish Prolonged Prophylaxis (DaPP) Study. Thromb Res. 1998 ; 89 (6). 281-287.
17. Prandoni P., Bruchi O., Sabbion P., et al. Prolonged thromboprophyalxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Arch Intern Med. 2002 ; 162 (17). 1966-1971.
18. Eriksson BI, Lassen MR ;. PENTasaccharide in HIpFRActure Surgery Plus Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2003 ; 163 (11). 1337-1342.
19. Eriksson BI, Dahl OE, Rosencher N., et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007 ; 370 (15). 949-956. (Pubitemid 47393577)
20. Kakkar AK, Brenner B., Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008 ; 372 (9632). 31-39.
21. Dickson BC Venous thrombosis: on the history of Virchows triad. UTMJ. 2004 ; 81: 166-171.
22. Warwick D., Martin AG, Glew D., Bannister GC Measurement of femoral vein blood flow during total hip replacement. Duplex ultrasound imaging with and without the use of a foot pump. J Bone Joint Surg Br. 1994 ; 76 (6). 918-921.
23. Dahl OE, Aspelin T., Lyberg T. The role of bone traumatization in the initiation of proximal deep vein thrombosis during cemented hip replacement surgery in pigs. Blood Coagul Fibrinolysis. 1995 ; 6 (8). 709-717.
24. Wilson D., Cooke EA, McNally MA Altered venous function and deep venous thrombosis following proximal femoral fracture. Injury. 2002 ; 33 (1). 33-39.
25. Planes A., Vochelle N., Fagola M. Total hip replacement and deep vein thrombosis. A venographic and necropsy study. J Bone Joint Surg Br. 1990 ; 72 (1). 9-13.
26. McNally MA, Bahadur R., Cooke EA, Mollan RA Venous haemodynamics in both legs after total knee replacement. J Bone Joint Surg Br. 1997 ; 79 (4). 633-637.
27. Sikorski JM, Hampson WG, Staddon GE The natural history and aetiology of deep vein thrombosis after total hip replacement. J Bone Joint Surg Br. 1981 ; 63-B (2). 171-177.
28. Dahl OE, Aspelin T., Arnesan H., et al. Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery. Thromb Res. 1995 ; 80 (4). 299-306.
29. Wilson D., Cooke EA, McNally MA Changes in coagul-ability as measured by thrombelastography following surgery for proximal femoral fracture. Injury. 2002 ; 32 (10). 765-770.
30. Strebel N., Prins M., Agnelli G., Büller HR Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery ? Arch Intern Med. 2002 ; 162 (13). 1451-1456.
31. Rosencher N., Bonnet MP, Sessler DI Selected new antithrombotic agents and neuraxial anaesthesia for major orthopaedic surgery: management strategies. Anaesthesia. 2007 ; 62 (11). 1154-1160.
32. Moen V., Dahlgren N., Irestedt L. Severe neurological complications after central neuraxial blockades in Sweden 1990-1999. Anesthesiology. 2004 ; 101 (4). 950-959.
33. Horlocker T., Wedel DJ, Benzon HT, et al. Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med. 2003 ; 28 (3). 172-197.
34. Tryba M. European practice guidelines: thromboembolism prophylaxis and regional anesthesia. Reg Anesth Pain Med. 1998 ; 23 (6 Suppl 2). 178-182.
35. Samama CM, Albaladejo P., Benhamou D., et al. Venous thromboembolism prevention in surgery and obstetrics: clinical practice guidelines. Eur J Anaesthesiol. 2006 ; 23 (2). 95-116.
36. Turpie AG, Bauer KA, Eriksson BI, Lassen MR Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopaedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002 ; 162 (16). 1833-1840.
37. Tribout B., Colin-Mercier F. New versus established drugs in venous thromboprophylaxis: efficacy and safety considerations related to timing of administration. Am J Cardiovasc Drugs. 2007 ; 7 (1). 1-15.
38. Bouma BN, Mosnier LO Thrombin activatable fibrinolysis inhibitor (TAFI) - how does thrombin regulate fibrinolysis? Ann Med. 2006 ; 38 (6). 378-388.
39. Vera-Llonch M., Hagiwara M., Oster G. Clinical and economic consequences of bleeding following major orthopedic surgery. Thromb Res. 2006 ; 117 (5). 569-577.
40. Aveline C., Bonnet F. Delayed retroperitoneal haematoma after failed lumbar plexus block. Br J Anaesth. 2004 ; 93 (4). 589-591.
41. Hsu DT Delayed retroperitoneal haematoma after failed lumbar plexus block. Br J Anaesth. 2005 ; 94 (3). 395.
42. Weller RS, Gerancher JC, Crews JC, Wade KL Extensive retroperitoneal hematoma without neurologic deficit in two patients who underwent lumbar plexus block and were later anticoagulated. Anesthesiology. 2003 ; 98: 581-585.
43. Hampson WG, Harris FC, Lucas HK, et al. Failure of low-dose heparin to prevent deep-vein thrombosis after hip-replacement arthroplasty. Lancet. 1974 ; 2 (7884). 795-797.
44. Robinson KS, Anderson DR, Gross M., et al. Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: the post-arthroplasty screening study. A randomized, controlled trial. Ann Intern Med. 1997 ; 127 (6). 439-445.
45. Ricotta S., Iorio A., Parise P., Nenci GG, Agnelli G. Post discharge clinically overt venous thromboembolism in orthopaedic surgery patients with negative venography-an overview analysis. Thromb Haemost. 1996 ; 76 (6). 887-892.
46. Warwick D., Samama MM The contrast between venographic and clinical endpoints in trials of thromboprophylaxis in hip replacement. J Bone Joint Surg Br. 2000 ; 82 (4). 480-482.
47. McNally MA, Mollan RA Total hip replacement, lower limb blood flow and venous thrombogenesis. J Bone Joint Surg Br. 1993 ; 75 (4). 640-644.
48. Warwick D., Williams MH, Bannister GC Death and thromboembolic disease after total hip replacement. A series of 1162 cases with no routine chemical prophylaxis. J Bone Joint Surg Br. 1995 ; 77 (1). 6-10.
49. Warwick DJ, Whitehouse S. Symptomatic venous thromboembolism after total knee replacement. J Bone Joint Surg Br. 1997 ; 79 (5). 780-786.
50. Lie SA, Engesaeter LB, Havelin LI, Gjessing HK, Vollset SE Mortality after total hip replacement: 0-10-year follow-up of 39,543 patients in the Norwegian Arthroplasty Register. Acta Orthop Scand. 2000 ; 71 (1). 19-27.
51. White RH, Romano PS, Zhou H., Rodrigo J., Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med. 1998 ; 158 (14). 1525-1531.
52. A Joint Report from The Royal College of Surgeons of England and the British Orthopaedic Association. National Total Hip Replacement Outcome Study. Final Report to the Department of Health. Revised June 2000. http://www.rcseng.ac.uk/publications/docs/hip-replacement.html/ attachment-download/pdffile. Accessed April 17, 2009.
53. Dahl OE, Gudmundsen TE, Bjørnarå BT, Solheim DM Risk of clinical pulmonary embolism after joint surgery in patients receiving low-molecular-weight heparin prophylaxis in hospital: a 10-year prospective register of 3,954 patients. Acta Orthop Scand. 2003 ; 74 (3). 299-304.
54. Colwell CW Jr, Collis DK, Paulson R., et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am. 1999 ; 81 (7). 932-940.
55. Mannucci PM, Citterio LE, Panajotopoulos N. Low-dose heparin and deep-vein thrombosis after total hip replacement. Thromb Haemost. 1976 ; 36 (1). 157-164.
56. Trowbridge A., Boese CK, Woodruff B., Brindley HH Sr, Lowry WE, Spiro TE Incidence of posthospitalization proximal deep venous thrombosis after total hip arthroplasty. A pilot study. Clin Orthop Relat Res. 1994 ; 299: 203-208.
57. Lassen MR, Borris LC, Anderson BS, et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty-the Danish Prolonged Prophylaxis (DaPP) Study. Thromb Res. 1998 ; 89 (6). 281-287.
58. Comp PC, Spiro TE, Friedman RJ, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am. 2001 ; 83-A (3). 336-345.
59. Heit JA Low-molecular-weight heparin: the optimal duration of prophylaxis against postoperative venous thromboembolism after total hip or knee replacement. Thromb Res. 2001 ; 101 (1). V163 - V173.
60. Rosencher N., Vielpeau C., Emmerich J., Fagnani F., Samama CM the ESCORTE group. Venous thromboembolism and mortality after hip fracture surgery: the ESCORTE study. J Thromb Haemost. 2005 ; 3 (9). 2006-2014.
61. Perez JV, Warwick DJ, Case CP, Bannister GC Death after proximal femoral fracture-an autopsy study. Injury. 1995 ; 26 (4). 237-240.
62. Todd CJ, Freeman CJ, Camilleri-Ferrante C., et al. Differences in mortality after fracture of hip: the east Anglian audit. BMJ. 1995 ; 310 (6984). 904-908.
63. Lawrence VA, Hilsenbeck SG, Noveck H., Poses RM, Carson JL Medical complications and outcomes after hip fracture repair. Arch Intern Med. 2002 ; 162 (18). 2053-2057.
64. Eikelboom JW, Quinlan DJ, Douketis JD Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet. 2001 ; 358 (9275). 9-15.
65. The Surgical Care Improvement Project. MedQIC. Oklahoma City, OK. Scip Project Information. www.medqic.org/dcs/ContentServer?cid= 1122904930422&pagename=Medqic%2FContent%2FParentShellTemplate& parentName=Topic&c=MQParents. Accessed April 17, 2009.
66. DH/CMO. Report of the independent expert working group on the prevention of venous thromboembolism in hospitalised patients, March 2007. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-073944?IdcService=GET-FILE&dID= 138346&Rendition=Web. Accessed April 17, 2009.